Cellectis S.A.
HealthcareNASDAQ:CLLS · NASDAQ Global Market
+$0.00 today
Vol 0.04M · Avg 0.04M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$68.1M of revenue converted into -$67.3M of net income for the selected period. Gross margin is 67.9% and net margin is -175.2%, showing how much revenue survives after costs and taxes. EPS is $-0.68, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.9M +75.8% | $41.5M +5397.5% | $755.0K -96.1% | $19.2M -36.8% | $30.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.8M +6.7% | $9.2M +23.8% | $7.4M -12.6% | $8.5M +360.1% | $1.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $63.2M +95.4% | $32.3M +585.1% | -$6.7M -162.4% | $10.7M -62.5% | $28.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 86.6% +8.7pp | 77.9% +960.5pp | -882.6% -938.4pp | 55.7% -38.2pp | 93.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $93.5M +3.3% | $90.5M +3.3% | $87.6M -10.1% | $97.5M -17.3% | $117.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $8.6M +2.1% | $8.4M +3.7% | $8.1M -8.7% | $8.9M -61.1% | $22.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $96.2M +4.7% | $91.9M +1.4% | $90.6M -9.7% | $100.4M -24.0% | $132.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $20.1M +1.1% | $19.8M +7.1% | $18.5M +0.5% | $18.4M +30.2% | $14.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$39.8M -321.1% | -$9.5M +89.8% | -$92.6M -21.3% | -$76.4M +2.6% | -$78.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -54.6% -31.8pp | -22.8% +12247.0pp | -12269.8% -11871.4pp | -398.4% -140.0pp | -258.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$33.1M +44.5% | -$59.6M +38.8% | -$97.3M -8.5% | -$89.7M +13.4% | -$103.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -45.3% +98.1pp | -143.5% +12744.2pp | -12887.7% -12420.0pp | -467.7% -126.7pp | -341.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.5M -15.8% | $11.3M +212.1% | $3.6M +222.7% | $1.1M +55.8% | $719.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $8.1M +8.8% | $7.5M +40.4% | $5.3M +40.1% | $3.8M -13.3% | $4.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$34.9M -253.3% | $22.8M +218.9% | -$19.2M -114.5% | -$8.9M -232.8% | $6.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$68.0M -85.0% | -$36.8M +68.4% | -$116.5M -18.1% | -$98.6M -1.9% | -$96.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -93.2% -4.7pp | -88.6% +15337.1pp | -15425.7% -14911.4pp | -514.3% -195.5pp | -318.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$423.0K | $0 -100.0% | $371.0K +326.4% | $87.0K +3000.0% | -$3.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$67.6M -83.9% | -$36.8M +63.6% | -$101.1M +4.8% | -$106.1M +7.1% | -$114.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -92.7% -4.1pp | -88.6% +13296.7pp | -13385.3% -12831.7pp | -553.6% -177.3pp | -376.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -65.9% | -$0 +76.8% | -$2 +24.0% | -$2 -20.7% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -65.9% | -$0 +76.8% | -$2 +24.0% | -$2 -20.7% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $100.3M +10.7% | $90.6M +58.9% | $57.0M +25.2% | $45.6M +1.6% | $44.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $100.3M +10.7% | $90.6M +58.9% | $57.0M +25.2% | $45.6M +1.6% | $44.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$889.71M
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
DBV Technologies S.A.
NASDAQ:DBVT
$416.60M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Mereo BioPharma Group plc
MREO
$48.68M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CLLS generate?
Cellectis S.A. (CLLS) reported $72.95M of revenue in fiscal 2025.
Is CLLS profitable?
Cellectis S.A. (CLLS) reported -$67,593,000.00 of net income, with a net margin of -92.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.